Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445515 | 0.89 | BTK (0.38) | ERN1BTKGPBAR1GABRA1 | |
| SCHEMBL6365092 | 0.84 | ALDH1A1 (0.38) | GPBAR1 | |
| SCHEMBL4962424 | 0.80 | ERN1 (0.51) | ERN1BTK | |
| SCHEMBL1543562 | 0.79 | ERN1 (0.41) | ERN1BTKGPBAR1 | |
| SCHEMBL29785434 | 0.78 | ERN1 (0.47) | ERN1GABRA1 | |
| SCHEMBL28311710 | 0.78 | ERN1 (0.47) | ERN1GABRA1 | |
| SCHEMBL14091647 | 0.75 | ERN1 (0.71) | ERN1 | |
| SCHEMBL12834046 | 0.75 | ERN1 (0.55) | ERN1BTK | |
| SCHEMBL12834050 | 0.74 | ERN1 (0.63) | ERN1 | |
| SCHEMBL12834051 | 0.74 | ERN1 (0.54) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | ERN1 140/4885BTK 2299/4885GPBAR1 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.